Rhumatologie

Treat to target in axial spondyloarthritis: From its concept to its implementation

Highlights

•A better knowledge of the natural history of spondyloarthritis permits to select surrogate markers of long term disability.
•Abrogation of inflammation should be the main target in axial spondyloarthritis.
•Other targets can be considered (e.g. NSAID intake reduction, treatment of predisposing factors to cardiovascular diseases).
•Novel therapies (e.g. TNF blockers, IL17 inhibitiors) are facilitating a teat to target approach.
•Implementation of a treat to target approach in spondyloarthritis should be further investigated.

https://doi.org/10.1016/j.jaut.2019.102398

MaximeDougados

Université de Paris, Department of Rheumatology – Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL
Rhumatologie

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL

Cost utility modeling of early vs late total knee replacement in osteoarthritis patients.
Rhumatologie

Cost utility modeling of early vs late total knee replacement in osteoarthritis patients.